The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).
At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a phase 2 study in which the investigational HIF-2α inhibitor MK-6482 showed durable efficacy in patients with Von Hippel-Lindau–associated RCC and non-renal lesions.
In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.
Related Content:Kidney Cancer